Nucleic acid detection compositions

• US 20050181435A1
• Filed: 04/12/2005
• Published: 08/18/2005
• Est. Priority Date: 01/24/1996
• Status: Active Grant

• Current Assignee: Gen-Probe Incorporated (Hologic Incorporated)
• Original Assignee: Third Wave Technologies Incorporated (Hologic Incorporated)
• Inventors: Prudent, James R., Hall, Jeff G., Dahlberg, James E., Lyamichev, Victor I., Brow, Mary Ann D.
• Granted Patent: US 7,407,782 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12N 9/22 Ribonucleases RNAses, DNAses catalytic nucleic acids C12N15/113
• CPC Class Codes: C12Q 1/6823 Release of bound markers
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/683 involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
• CPC Class Codes: C12Q 2525/301 Hairpin oligonucleotides
• CPC Class Codes: C12Q 2561/109 Invader technology
• CPC Class Codes: C12Q 2563/149 Particles, e.g. beads
• CPC Class Codes: C12Q 2565/525 characterised by the capture oligonucleotide being double stranded
• CPC Class Codes: Y10S 435/81 Packaged device or kit
• CPC Class Codes: Y10S 435/822 using bacteria or actinomycetales

Abstract

The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

Claims

1-25. -25. (canceled)

26. A composition for detecting a target nucleic acid, comprising:

a) a purified thermostable FEN-1 endonuclease; and

b) an oligonucleotide probe, said oligonucleotide probe configured to participate in a FEN-1 endonuclease cleavage structure in the presence of said target nucleic acid molecule.

27. The composition of claim 26, wherein said oligonucleotide probe comprises a label.

28. The composition of claim 27, wherein said label is configured to be detectable by a method comprising detection of fluorescence.

29. The composition of claim 27, wherein said label is configured to be detectable by a method comprising detection of mass.

30. The composition of claim 27, wherein said label is configured to be detectable by a method comprising detection of fluorescence energy transfer.

31. The composition of claim 27, wherein said label is configured to be detectable by a method comprising detection selected from the group consisting of detection of radioactivity, luminescence, phosphorescence, fluorescence polarization, and charge.

32. The composition of claim 26, wherein said thermostable FEN-1 endonuclease is from an archaebacterium.

33. The composition of claim 32, wherein said archaebacterium is Pyrococcus furiosus.

34. The composition of claim 32, wherein said archaebacterium is Methanococcus jannaschii.

35. The composition of claim 26, further comprising a nucleic acid molecule configured to hybridize to said target nucleic acid upstream of said oligonucleotide probe.

36. The composition of claim 35, wherein said oligonucleotide probe is configured to hybridize to a first region of said target nucleic acid, and wherein said nucleic acid molecule comprises a 5′

portion and a 3′

portion, said 5′

portion being configured to hybridize to a second region of said target nucleic acid, wherein said second region of said target nucleic acid is downstream of and contiguous to said first region of said target nucleic acid.

37. The composition of claim 36, wherein said 3′

portion of said nucleic acid molecule comprises an aromatic ring.

38. The composition of claim 36, wherein said 3′

portion of said nucleic acid molecule comprises a 3′

terminal nucleotide not complementary to said target nucleic acid.

39. The composition of claim 36, wherein said 3′

portion of said nucleic acid molecule consists of a single nucleotide.

40. The composition of claim 39, wherein said single nucleotide is not complementary to said target nucleic acid.

41. The composition of claim 39, wherein said single nucleotide is complementary to said target nucleic acid.

42. The composition of claim 38, wherein said 3′

terminal nucleotide comprises a naturally occurring nucleotide.

43. The composition of claim 38, wherein said 3′

terminal nucleotide comprises a nucleotide analog.

44. The composition of claim 36, wherein said 3′

portion of said nucleic acid molecule is completely complementary to said target nucleic acid.

45. The composition of claim 26, wherein said oligonucleotide probe is attached to a solid support.

46. The composition of claim 35, wherein said nucleic acid molecule is attached to a solid support.

47. The composition of claim 26, further comprising a polymerase enzyme.

48. The composition of claim 47, wherein said polymerase enzyme is altered to have reduced synthetic activity.

49. The composition of claim 26, further comprising said target nucleic acid.

50. The composition of claim 49, wherein said target nucleic acid comprises DNA.

51. The composition of claim 49, wherein said target nucleic acid comprises synthetic nucleic acid.

52. The composition of claim 51, wherein said synthetic nucleic acid comprises an amplified nucleic acid.

54. The composition of claim 36, wherein said composition further comprises a stacker oligonucleotide, wherein said stacker oligonucleotide is configured to hybridize to a third region of said target nucleic acid, and wherein said third region of said target nucleic acid is upstream of and contiguous to said first region of said target nucleic acid.

53. The composition of claim 53, wherein said amplified nucleic acid is produced using a polymerase chain reaction.